Sustained Intraperitoneal Paclitaxel Therapy in Ovarian Cancer
Author Information
Author(s): Vassileva V, Moriyama E H, De Souza R, Grant J, Allen C J, Wilson B C, Piquette-Miller M
Primary Institution: University of Toronto
Hypothesis
Does sustained intraperitoneal chemotherapy improve outcomes in ovarian cancer compared to intermittent therapy?
Conclusion
Sustained intraperitoneal paclitaxel therapy significantly reduced tumor growth and improved survival compared to intermittent therapy.
Supporting Evidence
- Sustained therapy resulted in significant reduction of tumor proliferation and weight.
- Bioluminescent imaging detected tumors earlier than traditional methods.
- Sustained therapy increased survival rates compared to intermittent therapy.
Takeaway
This study shows that giving cancer medicine directly into the belly can work better than giving it in bursts, helping mice with ovarian cancer live longer.
Methodology
Mice with ovarian cancer were treated with either sustained or intermittent paclitaxel therapy, and tumor growth was monitored using bioluminescent imaging.
Limitations
The study was conducted in a murine model, which may not fully replicate human responses.
Participant Demographics
Female SCID mice, aged 4-6 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website